In the
biotech market,
Becton, Dickinson and Company (BDX) has been quite active with several key developments and financial results. BDX reported on its
Q1 2026 financial results, revealing a mix of hits and misses in the first quarter. A
merger with Waters Corporation was also completed, combining their Biosciences and Diagnostic Solutions Business. Alongside this, post a life sciences sale update,
Citi raised BDX's Price Target to $198. Albeit, the company witnessed stock fluctuation and degradation to a
‘Strong Sell’ by Zacks Research. The firm has successfully managed to
beat Q1 earnings and revenue expectations. After a strategic spin-off and merger with Waters Corporation, Becton Dickinson is refocusing on MedTech. Price targets and ratings from numerous firms continue to be adjusted, reflecting a complex outlook. Becton Dickinson has also launched
$1.6 billion Debt Tender Offers and plans to pay a dividend of $1.05. The Company's board has even increased the dividend for the
54th consecutive year. Despite several challenges, there is robust faith in BDX’s durable growth potential.
Becton Dickinson and BDX News Analytics from Tue, 22 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 09:06:09 GMT -
Rating -3
- Innovation 5
- Information 8
- Rumor -6
